U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06813079) titled 'Using Tumor Models to Determine Treatments' on Feb. 03.
Brief Summary: The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.
Study Start Date: Feb. 17
Study Type: INTERVENTIONAL
Condition:
Advanced Epithelial Pancreatic Ductal Carcinoma
Intervention:
DRUG: Cobimetinib
Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway.
Participants will take cob...